Print Positron Emission Mammography (PEM)

Positron Emission Mammography (PEM)

 

DESCRIPTION

Positron emission mammography (PEM) is a form of positron emission tomography (PET) that uses a high-resolution, mini-camera detection technology for imaging the breast. As with PET, PEM provides functional rather than anatomic information on the breast. This policy will address the use of PEM for presurgical planning and staging, monitoring response to therapy, and monitoring for recurrence of breast cancer.

Positron emission mammography (PEM) is a form of positron emission tomography (PET) that uses a high-resolution, mini-camera detection technology for imaging the breast. As with PET, a radiotracer, usually 18F-fluorodeoxyglucose (FDG), is administered and the camera is used to provide a higher resolution image of a limited section of the body than would be achievable with FDG-PET. Gentle compression is used, and the detector(s) are mounted directly on the compression paddle(s). PEM allows for the detection of lesions smaller than 2 cm, which may not be possible with FDG-PET. It creates images that are more easily compared to mammography, since they are acquired in the same position. Three-dimensional reconstruction of the PEM images is also possible. As with PET, PEM provides functional rather than anatomic information on the breast.  

In August 2003, the PEM 2400 PET Scanner (PEM Technologies, Inc.) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The FDA determined that this device was substantially equivalent to existing devices for use in “medical purposes to image and measure the distribution of injected positron emitting radiopharmaceuticals in human beings for the purpose of determining various metabolic and physiologic functions within the human body.” In March 2009, the Naviscan PEM Flex Solo II High Resolution PET Scanner (Naviscan, Inc.) was cleared for marketing by the FDA through the 510(k) process for the same indication. The PEM 2400 PET Scanner was the predicate device. The newer device is described by the manufacturer as “a high spatial resolution, small field-of-view PET imaging system specifically developed for close-range, spot, i.e., limited field, imaging.”

There was a class 2 recall of the Naviscan PET Systems Inc. PEM Flex Solo II PET Scanner on September 11, 2008, due to “a report from a user indicating that the motorized compression exceeded 25 pounds of compression force during the pre-scan positioning of the patient.” At the time, there were 13 units on the market. Software for the PEM Flex Solo I and PEM Flex Solo II PET scanners was recalled in August 2007. 

Also, refer to related medical policy, Scintimammography/Breast-Specific Gamma Imaging/Molecular Breast Imaging. 

 

POLICY

The use of positron emission mammography (PEM) is considered investigational.

 

POLICY EXCEPTIONS

Federal Employee Program (FEP) may dictate that all FDA-approved devices, drugs or biologics may not be considered investigational and thus these devices may be assessed only on the basis of their medical necessity.

 

POLICY GUIDELINES

Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary.

The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.

 

POLICY HISTORY

03/31/2011: Approved by Medical Policy Advisory Committee.

07/17/2012: Policy reviewed; no changes.

10/23/2013: Policy reviewed; no changes.

 

SOURCE(S)

Blue Cross Blue Shield Association policy # 6.01.52 

 

CODE REFERENCE

This may not be a comprehensive list of procedure codes applicable to this policy.

Investigational Codes

Code Number

Description

CPT-4

78811

Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)

ICD-9 Procedure

 

 

ICD-9 Diagnosis

 

 

HCPCS

 

 

 

Top